Current trends in immunosuppressive therapies for renal transplant recipients

American Journal of Health-System Pharmacy

Volumn 69, Issue 22, 2012, Pages 1961-1975

  Lee, Ruth Ann ^a   Gabardi, Steven ^b,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CD3 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; DACLIZUMAB; EVEROLIMUS; GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; LCP TACRO; LEFLUNOMIDE; MERCAPTOPURINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR; XANTHINE OXIDASE;

ACUTE GRAFT REJECTION; ANEMIA; ANTIGEN PRESENTING CELL; AREA UNDER THE CURVE; BACTERIAL INFECTION; BIOEQUIVALENCE; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CONSTIPATION; CONTINUOUS INFUSION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER FAILURE; LIVER VENOOCCLUSIVE DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCELE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MICROEMULSION; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PANCREATITIS; PNEUMONIA; POSTTRANSPLANTATION DIABETES; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT WITHDRAWAL; TREND STUDY; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND HEALING IMPAIRMENT;

EID: 84869749211     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110624     Document Type: Review

References (89)

1. Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy. 2004; 24:1159-76.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004; 351:2715-29.
3. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant. 2002; 2:148-56.
4. Sandimmune (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011 Jul.
5. Prograf (tacrolimus) package insert. Deerfield, IL: Astellas Pharma US; 2011 Sep.
6. Reams BD, Palmer SM. Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. Am J Respir Med. 2002; 1:91-8.
7. Reams D, Rea J, Davis D et al. Utility of sublingual tacrolimus in cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2001; 20:207-8.
8. Alloway RR, Germain M, Osama G et al. A phase II open-label, multi-center prospective, conversion study in stable kidney transplant patients to compare the pharmacokinetics of LCP-Tacro tablets once a day to Prograf capsules twice a day. Presented at the American Transplant Congress. Toronto, Canada; 2008.
9. Collin C, Boussaud S, Lefeuvre C et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. Transplant Proc. 2010; 42:4331-7.
10. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9(suppl 3):S1-155.
11. Sukhpreet P. Therapeutic drug monitoring of immunosuppressants: an overview. Indian J Pharmacol. 2007; 39:66-70.
12. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007; 2:374-84.
13. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation. 2007; 83:1525-35.
14. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc. 2004; 36(suppl 2): S378-91.
15. Nulojix (belatacept) package insert. Princeton, NJ: Bristol-Myers Squibb; 2011 Jun.
16. Rapamune (sirolimus) package insert. Philadelphia: Wyeth Pharmaceuticals; 2010 Nov.
17. Zortress (everolimus) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010 Apr.
18. Imuran (azathioprine) package insert. Hunt Valley, MD: Prometheus Laboratories; 2011 Aug.
19. CellCept (mycophenolate mofetil) package insert. Nutley, NJ: Roche Laboratories; 2009 Oct.
20. Deltasone (prednisone) package insert. New York: Pharmacia and Upjohn Company; 2006 Aug.
21. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005; 16:3015-26.
22. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997; 63:977-83.
23. Vincenti F, Jensik SC, Filo RS et al. A longterm comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002; 73:775-82.
24. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000; 69:834-41.
25. Gonwa T, Johnson C, Ahsan N et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 2003; 75:2048-53.
26. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005; 331:810.
27. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001; 71:1282-7.
28. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab, and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007; 7:560-70.
29. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357:2562-75.
30. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in SYMPHONY study: observational results 3 years after transplantation. Am J Transplant. 2009; 8:1876-85.
31. Moore J, Middleton L, Cockwell P et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2009; 87:591-605.
32. Durrbach A, Francois H, Beaudreuil S et al. Advances in immunosuppression for renal transplantation. Nat Rev Nephrol. 2010; 6:160-7.
33. Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011; 31:394-407.
34. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant. 2010; 10:535-46.
35. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10:547-57.
36. Ferguson R, Grinyo J, Vincenti F et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011; 11:66-76.
37. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353:770-81.
38. Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010; 21:1587-96.
39. Rostaing L, Nainan G, del C Rial M et al. Switch from a CNI- to a belatacept-based immunosuppressive regimen in kidney transplant recipients is safe and results in better renal function: 12 month results from a Phase II study. Presented at the American Transplant Congress. San Diego, CA; 2010.
40. Morath C, Arns W, Schwenger V et al. Sirolimus in renal transplantation. Nephrol Dial Transplant. 2007; 22(suppl 8):viii61-5.
41. Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy. 2010; 30:1044-56.
42. MacDonald A, Scarola J, Burke JT et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000; 22(suppl B):B101-21.
43. Franco AF, Martini D, Abensur H et al. Proteinuria in transplant patients associated with sirolimus. Transplant Proc. 2007; 39:449-52.
44. Pinheiro HS, Amaro TA, Braga AM et al. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc. 2006; 38:3476-8.
45. Rangan GK. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf. 2006; 29:1153-61.
46. Ruiz JC, Campistol JM, Sanchez-Fructuoso A et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant. 2006; 21:3252-7.
47. Van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int. 2006; 70:1355-7.
48. Letavernier E, Pe'raldi MN, Pariente A et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation. 2005; 80:1198-203.
49. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without use of calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002; 74:1070-6.
50. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant. 2004; 4:1776-85.
51. Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation. 2007; 83:883-92.
52. Srinivas TR, Schold JD, Guerra G et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007; 7:586-94.
53. Flechner SM, Glyda M, Cockfield S et al. The ORION study: comparison of two sirolimus based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011; 11:1633-44.
54. Nashan B, Curtis J, Ponticelli C et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004; 78:1332-40.
55. Weir MR, Mulgaonkar S, Chan L et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011; 79:897-907.
56. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87:233-42.
57. Gabardi S, Tran JL, Clarkson MR. Entericcoated mycophenolate sodium. Ann Pharmacother. 2003; 37:1685-93.
58. Hardinger KL, Brennan DC, Lowell J et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int. 2004; 17:609-16.
59. Budde K, Curtis J, Knoll G et al. Entericcoated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004; 4:237-43.
60. Budde K, Knoll G, Curtis J et al. Longterm safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, Myfortic). Clin Nephrol. 2006; 66:103-11.
61. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004; 4:231-6.
62. Salvadori M, Holzer H, Civati G et al. Long-term administration of entericcoated mycophenolate sodium (EC-MPS; Myfortic) is safe in kidney transplant patients. Clin Nephrol. 2006; 66:112-9.
63. Chan L, Mulgaonkar S, Walker R et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006; 81:1290-7.
64. Shaw LM, Figurski M, Milone MC et al. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007; 2:1062-72.
65. Le Meur Y, Buchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007; 7:2496-503.
66. Van Gelder T, Silva HT, deFijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed dose concentration-controlled trial. Transplantation. 2008; 86:1043-51.
67. Gaston RS, Kaplan B, Shah T et al. Fixedor controlled-dose mycophenolate mofetil with standard- or reduced dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009; 9:1607-19.
68. Van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate in transplantation. Ther Drug Monit. 2006; 28:145-54.
69. Kuypers DR, Le Meur Y, Cantarovich M et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010; 5:341-58.
70. Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999; 68:261-6.
71. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation. 1997; 63:39. [Erratum, Transplantation. 1997; 63:618.]
72. Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet. 2004; 364:503-12.
73. Remuzzi G, Cravedi P, Costantini M et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007; 18:1973-85.
74. Shah S, Collett D, Johnson R et al. Longterm graft outcome with mycophenolate mofetil and azathioprine: a paired kidney analysis. Transplantation. 2006; 82:1634-9.
75. National Institute for Health and Clinical Excellence. Technology appraisal 85: immunosuppressive therapy for renal transplantation in adults, September 2004. www.nice.org.uklTA085guidance (accessed 2011 Jun 11).
76. Knight SR, Russell NK, Barcena L et al. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009; 87:785-94.
77. Veenstra DL, Best JH, Hornberger J et al. Incidence and long-term cost of steroidrelated side effects after renal transplantation. Am J Kidney Dis. 1999; 33:829-39.
78. Ojo AO, Hanson JA, Wolfe RA et al. Longterm survival in renal transplant recipients with graft function. Kidney Int. 2000; 57:307-13.
79. Kumar MS, Xiao SG, Fyfe B et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant. 2005; 19:61-9.
80. Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248:564-77.
81. Vitko S, Klinger M, Salmela K et al. Two corticosteroid-free regimens- tacrolimus monotherapy after basiliximab administration and tacrolimus/ mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation. 2005; 80:1734-41.
82. Vincenti F, Schena FP, Paraskevas S et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008; 8:307-16. [Erratum, Am J Transplant. 2008; 8:1080.]
83. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A metaanalysis. Transplantation. 2010; 89:1-14.
84. Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation. 1994; 58:443-73.
85. Opelz G, Döhler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant. 2005; 5:720-8.
86. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007; 76:391-6.
87. Manitpisitkul W, McCann E, Lee S et al. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens. 2009; 18:404-11.
88. Ensor CR, Trofe-Clark J, Gabardi S et al. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy. 2011; 31:1111-29.
89. Alloway R, Isaacs R, Lake K et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant. 2003; 3:1211-5.